Xencor (XNCR) Stock Price, News & Analysis

Company Overview

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California.

Key Stats

• Today's Range: $10.26 to $10.67
• 50-Day Range: $7.67 to $16.20
• 52-Week Range: $7.16 to $27.24
• Volume: 463,505 shs
• Average Volume: 628,717 shs
• Market Capitalization: $740.56 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $33.86
• Consensus Rating: Buy

Xencor Stock Analysis - MarketRank™

Xencor scored higher than 69% of companies evaluated by MarketBeat, and ranked 265th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Buy

Consensus Rating

Xencor has received a consensus rating of Buy. The company's average rating score is 3.13, and is based on 7 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Xencor has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Xencor are expected to grow in the coming year, from ($3.68) to ($3.64) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Xencor is -3.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Xencor is -3.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Xencor has a P/B Ratio of 0.96. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

11.75% of the float of Xencor has been sold short.

Short Interest Ratio / Days to Cover

Xencor has a short interest ratio ("days to cover") of 10.6, which indicates bearish sentiment.

Change versus previous month

Short interest in Xencor has recently increased by 9.87%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Xencor does not currently pay a dividend.

Dividend Growth

Xencor does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 3.9 / 5
• Environmental Score: -2.24

Percentage of Shares Shorted

11.75% of the float of Xencor has been sold short.

Short Interest Ratio / Days to Cover

Xencor has a short interest ratio ("days to cover") of 10.6, which indicates bearish sentiment.

Change versus previous month

Short interest in Xencor has recently increased by 9.87%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.78

News Sentiment

Xencor has a news sentiment score of 0.78. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.03 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 18 news articles for Xencor this week, compared to 4 articles on an average week.

MarketBeat Follows

1 people have added Xencor to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Xencor insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 5.23% of the stock of Xencor is held by insiders.

XNCR Stock Analysis - Frequently Asked Questions

How have XNCR shares performed this year?

Xencor's stock was trading at $22.98 on January 1st, 2025. Since then, XNCR shares have decreased by 54.3% and is now trading at $10.51.
View the best growth stocks for 2025 here.

How were Xencor's earnings last quarter?

Xencor, Inc. (NASDAQ:XNCR) announced its quarterly earnings results on Thursday, February, 27th. The biopharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.81) by $0.19. The biopharmaceutical company earned $52.79 million during the quarter, compared to analysts' expectations of $17.14 million. Xencor had a negative net margin of 232.77% and a negative trailing twelve-month return on equity of 30.92%.

Who are Xencor's major shareholders?

Top institutional shareholders of Xencor include Rhumbline Advisers (0.23%), Essex LLC (0.16%), New York State Teachers Retirement System (0.08%) and State of Alaska Department of Revenue (0.06%). Insiders that own company stock include Bassil I Dahiyat, John R Desjarlais, John J Kuch, Allen Yang, Celia Eckert, Alan Bruce Montgomery and Kurt A Gustafson.
View institutional ownership trends.

How do I buy shares of Xencor?

Shares of XNCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Xencor own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Xencor investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), AUO (AUOTY) and DiamondRock Hospitality (DRH).

Company Calendar

• Last Earnings: 2/27/2025
• Today: 4/26/2025
• Next Earnings (Estimated): 5/08/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:XNCR
• CIK: 1326732
• Web: www.xencor.com
• Phone: (626) 305-5900
• Fax: 626-305-0350
• Employees: 280
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $33.86
• High Stock Price Target: $40.00
• Low Stock Price Target: $28.00
• Potential Upside/Downside: +222.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.13
• Research Coverage: 8 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($3.51)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-126,090,000.00
• Net Margins: -232.77%
• Pretax Margin: -229.85%
• Return on Equity: -30.92%
• Return on Assets: -21.74%

Debt

• Debt-to-Equity Ratio: 0.01
• Current Ratio: 6.23
• Quick Ratio: 6.23

Sales & Book Value

• Annual Sales: $110.49 million
• Price / Sales: 6.70
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $10.99 per share
• Price / Book: 0.96

Miscellaneous

• Outstanding Shares: 70,462,000
• Free Float: 66,322,000
• Market Cap: $740.56 million
• Optionable: Optionable
• Beta: 0.90